AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14718459 — intervention group
Group type: COMPARATOR
Intervention: Premixed 50% nitrogen and oxygen (control group)
Number of subjects: 105
Study 15197055 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 408
Study 11106123 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 + LFA-5-FU (arm A)
Number of subjects: 159
Study 11106123 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM + LFA-5-FU (arm B)
Number of subjects: 159
Study 11106123 — intervention group
Group type: COMPARATOR
Intervention: MTX + LFA-5-FU (arm C)
Number of subjects: 159
Study 9083713 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-focused pharmacist intervention in community pharmacies; includes targeted patient education, systematic patient monitoring, feedback and behavior modification, and communication with physicians.
Number of subjects: 589
Study 9083713 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonparticipating pharmacies); no specific intervention reported.
Number of subjects: 589
Study 8246275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 25 mg
Number of subjects: 20
Study 8246275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 50 mg
Number of subjects: 20
Study 8246275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3532752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 0
Study 3532752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine + Propranolol
Number of subjects: 0
Study 3532752 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 30411132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare for kids (SFK)
Number of subjects: 180
Study 30411132 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 180
Study 27084959 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 100 mg
Number of subjects: 43
Study 27084959 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 200 mg
Number of subjects: 43
Study 27084959 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 300 mg
Number of subjects: 43
Study 27084959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 27084959 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-509 (all doses)
Number of subjects: 43
Study 24952856 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose, an α‐glucosidase inhibitor that lowers postprandial blood glucose
Number of subjects: 0
Study 24952856 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification or pharmacological intervention
Number of subjects: 0
Study 23167223 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Mosaic Ultra valve
Number of subjects: 141
Study 23167223 — intervention group
Group type: COMPARATOR
Intervention: Carpentier‐Edwards PERIMOUNT Magna valve
Number of subjects: 141
Study 20378636 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate testing and treatment for chlamydial infection
Number of subjects: 2529
Study 20378636 — intervention group
Group type: COMPARATOR
Intervention: Deferred screening controls
Number of subjects: 2529
Study 20378636 — intervention group
Group type: COMPARATOR
Intervention: Control women who tested positive for chlamydial infection at baseline
Number of subjects: 2529
Study 20378636 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened women who tested positive for chlamydial infection at baseline
Number of subjects: 2529
Study 20378636 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who tested negative for chlamydia at baseline
Number of subjects: 2529
Study 20378636 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall testing during the trial
Number of subjects: 2529
Study 18552239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-buffered fluid (LF)
Number of subjects: 91
Study 18552239 — intervention group
Group type: COMPARATOR
Intervention: Conventional acidic lactate-buffered fluid (CF)
Number of subjects: 91
Study 16925289 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally robotic laparoscopic Roux-en-Y gastric bypass (TRRYGB)
Number of subjects: 50
Study 16925289 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 50
Study 12538422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg subcutaneously twice daily)
Number of subjects: 746
Study 12538422 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (70-U/kg bolus; 15 U x kg(‐1) x h(‐1) infusion for 48 hours)
Number of subjects: 746
Study 10492111 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 and 18 testing in conjunction with repeat cytology
Number of subjects: 304
Study 10492111 — intervention group
Group type: COMPARATOR
Intervention: Repeat cytology alone
Number of subjects: 304
Study 8559201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles
Number of subjects: 392
Study 8559201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 8559201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg)
Number of subjects: 392
Study 1873266 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS Plus
Number of subjects: 2
Study 1873266 — intervention group
Group type: COMPARATOR
Intervention: S‐MA2
Number of subjects: 2
Study 6194568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric suction and intravenously administered fluids (SD)
Number of subjects: 50
Study 6194568 — intervention group
Group type: COMPARATOR
Intervention: Oral intake of clear fluids (FF)
Number of subjects: 50
Study 31070545 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin
Number of subjects: 715
Study 27520087 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone and hydroxypropyl methylcellulose (treatment group)
Number of subjects: 128
Study 27520087 — intervention group
Group type: COMPARATOR
Intervention: Topical dexamethasone (control group)
Number of subjects: 128
Study 25495859 — intervention group
Group type: EXPERIMENTAL
Intervention: Siphon water filter with educational messages
Number of subjects: 191
Study 23300977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis smoking (low Δ(9)‐Tetrahydrocannabinol blood concentrations)
Number of subjects: 31
Study 23300977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis smoking
Number of subjects: 31
Study 20736891 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive lumbar microdiscectomy
Number of subjects: 20
Study 20736891 — intervention group
Group type: COMPARATOR
Intervention: Open lumbar microdiscectomy
Number of subjects: 20
Study 19245362 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral iron supplementation (ferrous sulfate 325 mg three times daily)
Number of subjects: 200
Study 19245362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17135335 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 48
Study 17135335 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 48
Study 17135335 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 15133003 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (IR)
Number of subjects: 12
Study 15133003 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive group (IS)
Number of subjects: 12
Study 12100461 — intervention group
Group type: EXPERIMENTAL
Intervention: Various study designs (case-control, cohort, randomized trials)
Number of subjects: 0
Study 9821410 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ) without famotidine
Number of subjects: 0
Study 9821410 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ) with famotidine
Number of subjects: 0
Study 9821410 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ITZ with and without famotidine
Number of subjects: 0
Study 7655447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise in patients with essential hypertension (ESH)
Number of subjects: 37
Study 7655447 — intervention group
Group type: COMPARATOR
Intervention: Dynamic exercise in healthy controls (C)
Number of subjects: 37
Study 7655447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise in ESH with left ventricular hypertrophy (LVH+)
Number of subjects: 37
Study 7655447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise in ESH without left ventricular hypertrophy (LVH‐)
Number of subjects: 37
Study 2576360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10 mg picumast dihydrochloride
Number of subjects: 16
Study 2576360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 10 mg picumast dihydrochloride
Number of subjects: 16
Study 2576360 — intervention group
Group type: COMPARATOR
Intervention: Comparison to healthy subjects
Number of subjects: 16
Study 796401 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 gms. galactose
Number of subjects: 18
Study 796401 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 gms. arabinogalactan and 0.11 gm. sodium saccharin
Number of subjects: 18
Study 796401 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 gm. methyl cellulose and 0.083 gm. sodium saccharin
Number of subjects: 18
Study 796401 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 gm. galactose
Number of subjects: 18
Study 7011356 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.05% (Eumovate)
Number of subjects: 2
Study 7011356 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone butyrate 0.1% (Locoid)
Number of subjects: 2
Study 31597151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis 3 times a week for 4 months
Number of subjects: 30
Study 31597151 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 30
Study 29672965 — intervention group
Group type: EXPERIMENTAL
Intervention: 103-mg p-synephrine (S)
Number of subjects: 16
Study 29672965 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + 104-mg p-synephrine
Number of subjects: 16
Study 29672965 — intervention group
Group type: EXPERIMENTAL
Intervention: 240-mg caffeine
Number of subjects: 16
Study 29672965 — intervention group
Group type: EXPERIMENTAL
Intervention: 337-mg caffeine + 46-mg p-synephrine
Number of subjects: 16
Study 29672965 — intervention group
Group type: EXPERIMENTAL
Intervention: 325-mg caffeine
Number of subjects: 16
Study 29672965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study 27012397 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR in patients aged ≥90 years
Number of subjects: 3773
Study 27012397 — intervention group
Group type: COMPARATOR
Intervention: TAVR in patients aged <90 years
Number of subjects: 3773
Study 24461464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration of local ropivacaine (CWI group, n=29)
Number of subjects: 60
Study 24461464 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl and ketorolac infusion on demand by patient‐controlled analgesia (IV PCA group, n=31)
Number of subjects: 60
Study 21883496 — intervention group
Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA) at 2 mg/kg
Number of subjects: 90
Study 21883496 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (ISO) at 600 mg/kg
Number of subjects: 90
Study 21883496 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous addition of ZEA and ISO
Number of subjects: 90
Study 21883496 — intervention group
Group type: EXPERIMENTAL
Intervention: Zearalenone (ZEA)
Number of subjects: 90
Study 19488681 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (1,830 mg/day) for 30 days
Number of subjects: 20
Study 19488681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 20
Study 17335689 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (growth factors)
Number of subjects: 0
Study 17335689 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors as chemotherapy-sensitizing agents
Number of subjects: 0
Study 17335689 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factor monotherapy
Number of subjects: 0
Study 17335689 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors administration
Number of subjects: 0
Study 17335689 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors in younger patients with acute myeloid leukemia with normal karyotype
Number of subjects: 0
Study 12781094 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS (100 mg/day) on awakening
Number of subjects: 64
Study 12781094 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS (100 mg/day) before bedtime
Number of subjects: 64
Study 12781094 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological hygienic-dietetic recommendations
Number of subjects: 64
Study 10682031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin (6 mg/kg/day, n = 21)
Number of subjects: 38
Study 10682031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 38
Study 9100167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg/kg, intravenously, once on admission), colchicine (0.5 mg, orally, daily, for 3 days), pentoxifylline (400 mg, orally, daily, for 3 days)
Number of subjects: 26
Study 9100167 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given DCP)
Number of subjects: 26
Study 8402761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (300 mg t.i.d.; n = 143)
Number of subjects: 281
Study 8402761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 138)
Number of subjects: 281
Study 3781678 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose: CHL 25 mg and MET 200 mg
Number of subjects: 73
Study 3781678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose: CHL 12.5 mg and MET 100 mg
Number of subjects: 73
Study 3781678 — intervention group
Group type: COMPARATOR
Intervention: Higher dose (standard dose) vs Lower dose
Number of subjects: 73
Study 27749603 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily) with Raltegravir (400 mg twice daily, Arm1)
Number of subjects: 343
Study 27749603 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily) with Tenofovir/Emtricitabine (245/200 mg once daily, Arm2)
Number of subjects: 343
Study 26474979 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention including web-enabled device, training sessions, coaching, clinician education
Number of subjects: 0
Study 26474979 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study 23414551 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing monounsaturated fat (MUFA)
Number of subjects: 34
Study 23414551 — intervention group
Group type: COMPARATOR
Intervention: Diet containing butter fat (SFA)
Number of subjects: 34
Study 23414551 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with long-chain n-3 fatty acids
Number of subjects: 34
Study 20096545 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester (staest) spread (2 g/day) for four weeks
Number of subjects: 22
Study 20096545 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol ester (steest) spread (2 g/day) for four weeks
Number of subjects: 22
Study 19900235 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 51
Study 19900235 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin
Number of subjects: 51
Study 19900235 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 51
Study 17326149 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoleucine infusion
Number of subjects: 16
Study 17326149 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 16
Study 15358024 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/exercise intervention
Number of subjects: 353
Study 15358024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 353
Study 11485010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous magnetic field exposure
Number of subjects: 24
Study 11485010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent magnetic field exposure
Number of subjects: 24
Study 11485010 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exposure)
Number of subjects: 24
Study 10984298 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin treatment (rhGH, 12 microg/kg/day) for 6 months
Number of subjects: 20
Study 10984298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8181259 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat diet
Number of subjects: 25
Study 8181259 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet
Number of subjects: 25
Study 8181259 — intervention group
Group type: COMPARATOR
Intervention: High saturated fat baseline diet
Number of subjects: 25
Study 3310721 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 0.005 mg/kg
Number of subjects: 92
Study 3310721 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg
Number of subjects: 92
Study 3310721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 92
Study 31852410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial thrombolysis (recombinant tissue plasminogen activator, 0.5 mg/ml, maximum dose limit 22.5 mg)
Number of subjects: 200
Study 31852410 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial placebo
Number of subjects: 200
Study 31852410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial thrombolysis
Number of subjects: 200
Study 31969360 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage revision surgery
Number of subjects: 57
Study 31969360 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage revision surgery
Number of subjects: 57
Study 30481596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone prophylaxis (group B)
Number of subjects: 228
Study 28775279 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaching fraction of 0.29
Number of subjects: 0
Study 28775279 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in irrigation water salinity (ECiw)
Number of subjects: 0
Study 28775279 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in leaching fraction (LF)
Number of subjects: 0
Study 25294647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells (BMMCs)
Number of subjects: 200
Study 25294647 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMCs)
Number of subjects: 200
Study 25294647 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 200
Study 22884376 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent running lights mounted to bicycles
Number of subjects: 3845
Study 22884376 — intervention group
Group type: COMPARATOR
Intervention: Control group without bicycle running lights
Number of subjects: 3845
Study 20974293 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 240
Study 20974293 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 240
Study 20032546 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha2a 180 microg/week plus ADV 10 mg/day
Number of subjects: 60
Study 20032546 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha2a monotherapy
Number of subjects: 60
Study 18028568 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback and education intervention at site 1
Number of subjects: 59
Study 18028568 — intervention group
Group type: COMPARATOR
Intervention: Control group at site 2 (no feedback or education)
Number of subjects: 59
Study 14973216 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg per day)
Number of subjects: 149
Study 14973216 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg per day)
Number of subjects: 149
Study 14973216 — intervention group
Group type: COMPARATOR
Intervention: Reference group (27 untreated patients)
Number of subjects: 149
Study 11281392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (Pnc PS)
Number of subjects: 44
Study 9677439 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose IL-2/IFN-alpha combination therapy (protocol 1)
Number of subjects: 67
Study 9677439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose, long-term continuous IFN-alpha/IL-2 administration (protocol 2)
Number of subjects: 67
Study 9677439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose IFN-alpha and 13-cis-retinoic acid therapy in repetitive weekly cycles (protocol 3)
Number of subjects: 67
Study 9677439 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 67
Study 7988246 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant intrapleural bacillus Calmette‐Guérin (BCG)
Number of subjects: 473
Study 7988246 — intervention group
Group type: COMPARATOR
Intervention: Saline solution placebo control
Number of subjects: 473
Study 2735177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg ATR
Number of subjects: 44
Study 2735177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg DTC
Number of subjects: 44
Study 2735177 — intervention group
Group type: COMPARATOR
Intervention: Saline (NS)
Number of subjects: 44
Study 29567335 — intervention group
Group type: EXPERIMENTAL
Intervention: Family nursing therapeutic conversations (FNTC) as a supplement to usual care
Number of subjects: 347
Study 29567335 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 347
Study 28244559 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW+ resistance exercise (1x60 repetitions at 20%1RM followed by 1x10-20 repetitions at 40%1RM)
Number of subjects: 47
Study 28244559 — intervention group
Group type: COMPARATOR
Intervention: HIGH-resistance (2x10-15 repetitions at 80%1RM)
Number of subjects: 47